AHIP, a group that represents the insurance industry, maintains that there is not yet enough evidence to show the drugs are effective options for long-term weight loss
Zepbound, DailyMed (2025) Analysis of tirzepatide acquisition costs and weight reduction outcomes in the United Kingdom: Insights from the SURMOUNT-1 study, Advances in Therapy (2025) The role of lifestyle modification with second-generation anti-obesity medications: Comparisons, questions, and clinical opportunities, Current Obesity Reports (2023) Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial, Endocrine (2024) Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis, Cureus (2023) Tirzepatide once weekly for the treatment of obesity, The New England Journal of Medicine (2022) Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial, Journal of the American Medical Association (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Some online myths claim these nutrients can cure chronic diseases overnight
Research in patients taking GLP-1 medications shows that baseline kidney function remains stable in most people, but those with pre-existing chronic kidney disease (CKD) require closer monitoring
